2026 may finally be the year Alpha Tau Medical ( DRTS ), an under-the-radar Israeli micro-cap, finally shakes off its obscurity. The firm is quietly developing a significant breakthrough in oncology, pioneering the first way of delivering alpha particleSean Daly writes on ETFs, biotech and FINTECH solutions in the banking space. He teaches international finance and financial risk management at Pace University and was a visiting lecturer at Princeton University from 2005 to 2009. He was educated at Columbia ...

Summary of Alpha Tau Conference Call Company Overview - **Company**: Alpha Tau Medical - **Product**: Alpha DaRT, a local intratumoral injection delivering alpha particle radiation directly into tumors, which is more efficient than traditional radiation therapies [2][3] Key Updates and Developments - **Transformative Year**: 2026 is expected to be a transformative year for Alpha Tau, with significant advancements in their clinical studies and regulatory approvals [2][15] - **FDA Programs**: Alpha Tau is part of the FDA's Total Product Lifecycle Advisory Program (TAP), which helps accelerate the commercial pathway for therapies [5] Clinical Trials and Data - **Pancreatic Cancer Study**: Data presented at the ASCO GI conference showed promising safety and disease control, with no significant immune suppression observed [6][8] - **FDA Submission**: A rolling submission for approval of Alpha DaRT in recurrent cutaneous squamous cell carcinoma (SCC) has begun, allowing for modular submissions to expedite the process [9][10] - **Japan Approval**: Alpha DaRT received approval in Japan for locally advanced unresectable and locally recurrent head and neck cancer, marking the first approval outside of Israel [11][12] - **Market Potential**: In the U.S., there are approximately 1.8 million new cutaneous SCC cases annually, with an estimated target market of 64,000 cases for Alpha DaRT [29][30] Market Strategy - **Focus on Difficult Cases**: Alpha Tau aims to target patients with difficult-to-treat cancers, particularly those with local recurrences or nodal spread [30] - **Partnerships**: The company is exploring partnerships for distribution and commercialization, particularly in Japan, and is open to collaborations on combination therapies with checkpoint inhibitors [38][39][42] Financial Position - **Cash Reserves**: Alpha Tau reported $77 million in cash and deposits at the end of the year, with a burn rate of $5-$6 million per quarter for operations [22][23] Future Outlook - **Upcoming Milestones**: Key studies in skin cancer, pancreatic cancer, and glioblastoma are expected to yield significant data in the second half of the year [17][21] - **Transformative Changes**: The company anticipates a substantial transformation by next year, driven by the outcomes of pivotal studies and potential new partnerships [48] Additional Considerations - **Regulatory Challenges**: Japan's regulatory environment is noted as challenging, but the approval is seen as a validation of Alpha DaRT's potential [11][12] - **Operational Stability**: Despite regional military actions, Alpha Tau has not experienced material disruptions to its operations [45] This summary encapsulates the key points from the conference call, highlighting Alpha Tau's innovative approach to cancer treatment, recent achievements, and strategic direction moving forward.

Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of the Alpha DaRT for treating solid tumors [2] - The technology behind Alpha DaRT was developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University [2] Product Information - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed for highly potent and conformal alpha-irradiation of solid tumors through intratumoral delivery of radium-224 impregnated sources [3] - The therapy aims to destroy tumors by releasing high-energy alpha particles from decaying radium, which primarily affects the tumor while sparing surrounding healthy tissue due to the short diffusion distance of alpha-emitting atoms [3] Upcoming Events - CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference on March 18, 2026, from 10:00 to 10:30 AM ET, and will be available for one-on-one investor meetings [1]

Financial Reporting and Accounting Standards - The company prepares its consolidated financial statements in accordance with U.S. GAAP, requiring estimates and judgments that affect reported amounts of assets, liabilities, and expenses [696]. - Share-based compensation is accounted for under ASC No. 718, requiring the estimation of fair value of equity-based payment awards on the grant date using an option-pricing model [698]. - The company recognizes share-based compensation expense for graded vesting awards on a straight-line basis over the requisite service period, and for performance condition awards, expense is recognized when it is probable that the condition will be achieved [699]. - The fair value of warrants issued during the Merger is classified as a liability and is subject to re-measurement at each balance sheet date until exercised [701]. - The expected term of options is determined using a simplified method, averaging the time-to-vesting and the contractual life of the options [703]. - The fair value of Ordinary shares is determined based on the closing price on NASDAQ on the date of grant, with input from third-party valuation specialists [703]. Foreign Currency Exchange Risk - A 10% unfavorable movement in foreign currency exchange rates would have increased operating expenses by approximately 4.7% and 5.6% for the years ended December 31, 2024 and 2025, respectively [689]. - The company does not currently hedge its foreign currency exchange rate risk but may consider formal currency hedging transactions in the future [690]. Corporate Governance and Compliance - The company intends to rely on exemptions under the JOBS Act, including exemptions from auditor's attestation reports on internal controls until certain revenue thresholds are met [692]. Dividend Policy - The company does not anticipate paying any dividends in the foreseeable future, using 0% as the expected dividend yield [703].

Core Insights - Alpha Tau Medical Ltd. reported a strong financial position with $76.9 million in cash and equivalents, supporting clinical advancements and commercial preparations [1][12] - The company has made significant progress in clinical trials and received marketing approval in Japan, marking a pivotal moment for its Alpha DaRT technology [2][4] Financial Performance - For the year ended December 31, 2025, R&D expenses increased to $32.1 million from $27.0 million in 2024, driven by higher employee compensation, raw material costs, and contractor expenses [8] - Marketing expenses decreased to $1.9 million from $2.3 million in 2024, while G&A expenses rose to $8.4 million from $6.7 million, primarily due to increased compensation and professional fees [9] - The company reported a net loss of $42.6 million, or $0.53 per share, compared to a net loss of $31.8 million, or $0.45 per share, in 2024 [11][23] Clinical and Regulatory Developments - Alpha Tau received marketing approval in Japan for Alpha DaRT in treating unresectable locally advanced or locally recurrent head and neck cancer, requiring a post-market surveillance study [6] - The company has five clinical trials approved in the U.S., including pivotal trials for skin cancer and pancreatic cancer, with significant milestones expected in the coming months [4][5] - Positive data from pancreatic cancer trials showed a 22% objective response rate and an 81% disease control rate across 32 patients [6] Manufacturing and Strategic Initiatives - Alpha Tau announced the receipt of a radioactive material license for its New Hampshire manufacturing facility, enabling commercial-scale production of Alpha DaRT [5] - The company is focused on expanding its manufacturing capabilities and engaging in strategic dialogues with potential partners to enhance the prospects for Alpha DaRT [2]

(NASDAQ:DRTS) Investor Presentation 1 Disclaimer This presentation (together with oral statements made in connection herewith, the "Presentation") is for informational purposes only to assist interested parties in making their own evaluation with respect to Alpha Tau Medical Ltd. ("Alpha Tau" or the "Company"). By accepting this Presentation, you acknowledge and agree that all of the information contained herein or disclosed orally during this Presentation is confidential, that you will not distribute, repr ...

Core Viewpoint - H.C. Wainwright analyst Yi Chen has raised the price target for Alpha Tau (DRTS) to $12 from $9, maintaining a Buy rating following Japan's Ministry of Health, Labour and Welfare granting marketing approval for Alpha DaRT to treat unresectable locally advanced or locally recurrent head and neck cancer [1] Group 1 - The approval in Japan validates the Alpha DaRT platform [1] - The approval helps to de-risk clinical development in the U.S. [1]

Core Viewpoint - HekaBio K.K. has successfully led the approval process for Alpha DaRT, an innovative solid tumor treatment device, in Japan, marking it as the first country outside of Israel to approve this therapy [1][2]. Group 1: Product Approval and Market Launch - Japan is the first country outside of Israel to approve Alpha DaRT for treating unresectable locally advanced or recurrent head and neck cancer, providing a new therapeutic option where conventional treatments have failed [2][3]. - HekaBio will be responsible for launching Alpha DaRT in the Japanese market as the Designated Marketing Authorization Holder (DMAH) [1][2]. Group 2: Technology and Mechanism of Action - Alpha DaRT utilizes Ra-224 atoms inserted into solid tumors, which decay and release alpha particles that damage the DNA of tumor cells, leading to cell death [3][6]. - The treatment is highly localized due to the short range of alpha particles, minimizing damage to surrounding healthy tissue [6][10]. Group 3: Clinical Significance and Future Directions - Clinical trials in Japan have shown that Alpha DaRT has strong potential for treating cancers that do not respond to standard therapies, marking a significant clinical milestone [4][5]. - The CEO of Alpha Tau Medical emphasized the importance of this approval as a first step towards broader clinical evaluation and potential reimbursement discussions with the MHLW in Japan [5][7]. Group 4: Company Background - HekaBio K.K. is a biopharma and MedTech venture focused on commercializing early-stage assets in Japan and the Asia-Pacific region, with a portfolio emphasizing innovations in oncology [8][9]. - Alpha Tau Medical, founded in 2016, specializes in oncology therapeutics and the development of Alpha DaRT for solid tumors [10].

Core Insights - Alpha Tau Medical Ltd. has received regulatory marketing approval for its Alpha DaRT cancer therapy in Japan, marking the first approval outside of Israel [1][2][3] - The approval is a significant milestone for the company and reflects strong collaboration with Japanese regulators and clinical societies [1][3] Regulatory Approval - The Shonin approval process in Japan is known for its rigor, requiring a review by the Pharmaceuticals and Medical Devices Agency (PMDA) [2] - As part of the approval, Alpha Tau will conduct a post-market surveillance study involving 66 patients across five clinical centers in Japan to assess the safety and clinical performance of Alpha DaRT [2] Clinical Significance - The Alpha DaRT platform is designed to deliver intra-tumoral alpha-emitting radiotherapeutics, which has shown promise in treating unresectable locally advanced or locally recurrent head and neck cancer [1][7] - The therapy aims to provide a new treatment option for patients who have not responded to conventional therapies, potentially expanding the range of treatment options available [4][5] Collaboration and Future Plans - Alpha Tau plans to work closely with Japanese clinicians to complete the post-market surveillance study and generate high-quality clinical data [3] - The company anticipates discussions with the MHLW regarding potential reimbursement approaches for Alpha DaRT in Japan, aiming for broader clinical evaluation and potential studies for additional tumor types [3] Company Background - Alpha Tau Medical Ltd. was founded in 2016 and focuses on the research, development, and commercialization of Alpha DaRT for solid tumors [6] - The technology was developed by researchers from Tel Aviv University and aims to deliver targeted alpha-irradiation to tumors while sparing healthy tissue [7]

Core Insights - Alpha Tau Medical Ltd. is preparing for a highly active clinical year in 2026, with significant patient recruitment and data readouts expected from various cancer trials, including the ReSTART pivotal trial for skin cancer and studies for internal organ cancers [1][12] Clinical Trials and Developments - The company is conducting multiple significant clinical trials globally, with five approved trials in the U.S. and additional trials in France, Italy, and the UK, focusing on various cancer types [2][3] - Ongoing trials include treatments for prostate, lung, and pancreatic tumors, as well as a pivotal trial for recurrent cutaneous squamous cell carcinoma (cSCC) [3][5] - The company is targeting completion of patient recruitment for the pancreatic cancer study by the end of Q1 2026, with initial results expected by year-end [7] - Initial results from the glioblastoma multiforme (GBM) trial are anticipated around the end of Q4 2026, with a cautious approach to patient enrollment [8] Regulatory and Commercial Readiness - Alpha Tau is awaiting a response from Japan's Ministry of Health regarding approval for Alpha DaRT in treating recurrent head and neck cancer, which would mark its first commercial approval outside Israel [9] - The company is preparing for potential post-marketing surveillance in Japan and is also exploring a new clinical trial combining Alpha DaRT with checkpoint inhibitors for advanced head and neck cancer [10] - Manufacturing capabilities are being ramped up in Jerusalem and a new facility in New Hampshire, with a focus on scaling production and enhancing operational efficiency [15][16] Financial Position and Strategic Outlook - The company maintains a stable cash burn rate and is confident in its ability to execute current plans, having filed over 60 new patent applications in 2025 [17][18] - Increased recognition of Alpha DaRT's relevance in oncology is leading to strategic discussions with potential partners for collaboration [19] - The company anticipates a busy and challenging year in 2026, building on the successes of 2025 and aiming to achieve set goals [20]